InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of InflaRx (NASDAQ:IFRX - Free Report) in a research note published on Friday,Benzinga reports. They currently have a $8.00 price target on the stock.

InflaRx Stock Performance

Shares of IFRX stock traded up $0.11 during mid-day trading on Friday, reaching $2.24. 88,739 shares of the company were exchanged, compared to its average volume of 188,125. InflaRx has a fifty-two week low of $1.16 and a fifty-two week high of $2.82. The company has a market capitalization of $131.90 million, a P/E ratio of -2.07 and a beta of 1.67. The business's 50 day simple moving average is $1.93 and its 200 day simple moving average is $1.67.

InflaRx Company Profile

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.